Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adma Biologics (ADMA) Prepaid Assets (2016 - 2025)

Adma Biologics' Prepaid Assets history spans 14 years, with the latest figure at $7.5 million for Q4 2025.

  • For Q4 2025, Prepaid Assets fell 7.11% year-over-year to $7.5 million; the TTM value through Dec 2025 reached $7.5 million, down 7.11%, while the annual FY2025 figure was $7.5 million, 7.11% down from the prior year.
  • Prepaid Assets reached $7.5 million in Q4 2025 per ADMA's latest filing, up from $6.9 million in the prior quarter.
  • In the past five years, Prepaid Assets ranged from a high of $9.5 million in Q3 2024 to a low of $3.7 million in Q1 2024.
  • Average Prepaid Assets over 5 years is $6.1 million, with a median of $5.5 million recorded in 2022.
  • The largest YoY upside for Prepaid Assets was 129.59% in 2025 against a maximum downside of 27.4% in 2025.
  • A 5-year view of Prepaid Assets shows it stood at $4.3 million in 2021, then rose by 17.42% to $5.1 million in 2022, then grew by 4.69% to $5.3 million in 2023, then surged by 50.52% to $8.0 million in 2024, then fell by 7.11% to $7.5 million in 2025.
  • Per Business Quant, the three most recent readings for ADMA's Prepaid Assets are $7.5 million (Q4 2025), $6.9 million (Q3 2025), and $8.1 million (Q2 2025).